Erbitux® (cetuximab) Injectable Medication Precertification Request

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:			
Address:	City:	State:	ZIP:	
Home Phone:	Work Phone:	Cell Phone:		
DOB:	Allergies:	Email:		

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:	City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:	Office Contact Name:	Phone:			

Specialty *(Check one):* ☐ **Oncologist** ☐ **Hematologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other: _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for Erbitux: Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required for all requests):

☐ **Colorectal cancer (including appendiceal carcinoma, and anal carcinoma)**
What is the clinical setting in which Erbitux will be used? ☐ Unresectable/inoperable disease ☐ Advanced disease ☐ Metastatic disease
☐ Other- please explain: _____
Please indicate the patient's RAS (KRAS and NRAS) mutation status: ☐ Negative (wild-type) for KRAS and NRAS mutations
☐ Positive for KRAS and/or NRAS mutation(s) ☐ Unknown
☐ Yes ☐ No Has the patient previously experienced clinical failure on panitumumab (Vectibix)?
☐ Yes ☐ No Will Erbitux be used in combination with encorafenib (Braftovi)?
→ ☐ Yes ☐ No ☐ Unknown Is the tumor positive for BRAF V600E mutation?

☐ **Non-small cell lung cancer**
☐ Yes ☐ No Will the requested drug be used in combination with afatinib (Gilotrif)?
☐ Yes ☐ No Does the patient have a known sensitizing epidermal growth factor receptor (EGFR) mutation?
☐ Yes ☐ No Has the patient progressed on EGFR tyrosine kinase inhibitor therapy (e.g. afatinib, erlotinib, gefitinib)?
What is the place in therapy in which the requested drug will be used? ☐ Initial treatment ☐ Subsequent treatment
What is the clinical setting in which Erbitux will be used? ☐ Recurrent disease ☐ Advanced disease ☐ Metastatic disease
☐ Other- please explain: _____

☐ **Occult primary head and neck cancer**
☐ Yes ☐ No Will the requested drug be used as a single agent?
☐ Yes ☐ No Will the requested drug be used for sequential chemoradiation?

Continued on next page

Erbitux® (cetuximab) Injectable Medication Precertification Request

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Penile cancer**
☐ Yes ☐ No Will the requested drug be used as a single agent?
What is the place in therapy in which the requested drug will be used? ☐ Initial treatment ☐ Subsequent treatment
What is the clinical setting in which Erbitux will be used? ☐ Metastatic disease ☐ Other- please explain: _____

☐ **Squamous cell carcinoma of the head and neck**
☐ Yes ☐ No Is the patient unfit for surgery?
☐ Yes ☐ No Will the requested drug be used in combination with radiation?
What is the clinical setting in which Erbitux will be used? ☐ Locally or regionally advanced disease ☐ Unresectable disease
☐ Recurrent disease ☐ Persistent disease ☐ Metastatic disease
☐ Other- please explain: _____

☐ **Squamous cell skin cancer**
What is the clinical setting in which Erbitux will be used? ☐ Inoperable disease ☐ Incompletely resected regional disease
☐ Disease with distant metastases ☐ Other- please explain: _____

For continuation of therapy:
☐ Yes ☐ No Is there evidence of disease progression or unacceptable toxicity on the current regimen?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.